tetano
Editor, Senior Moderator
PLoS One
. 2022 Dec 22;17(12):e0278214.
doi: 10.1371/journal.pone.0278214. eCollection 2022.
Delirium in hospitalized COVID-19 patients: Predictors and implications for patient outcome
Vera Wilke[SUP] 1 2 [/SUP], Mihaly Sulyok[SUP] 3 [/SUP], Maria-Ioanna Stefanou[SUP] 4 [/SUP], Vivien Richter[SUP] 5 [/SUP], Benjamin Bender[SUP] 5 [/SUP], Ulrike Ernemann[SUP] 5 [/SUP], Ulf Ziemann[SUP] 1 2 [/SUP], Nisar Malek[SUP] 6 [/SUP], Katharina Kienzle[SUP] 7 [/SUP], Constantin Klein[SUP] 6 [/SUP], Stefanie Bunk[SUP] 6 [/SUP], Siri Goepel[SUP] 6 7 [/SUP], Annerose Mengel[SUP] 1 2 [/SUP]
Affiliations
Abstract
Introduction: Delirium is recognized as a severe complication of coronavirus-disease-2019 (COVID-19). COVID-19-associated delirium has been linked to worse patient outcomes and is considered to be of multifactorial origin. Here we sought to evaluate the incidence and risk factors of delirium in hospitalized COVID-19 patients, along with its impact on clinical outcome.
Methods: Consecutive adult COVID-19 patients admitted to a tertiary academic referral hospital between March 1st and December 31st, 2020 were included. Potential risk factors for delirium were evaluated, including: age, gender, disease severity (as per the highest WHO grading reached during admission), laboratory parameters for infection and renal function (as per their most extreme values), and presence of comorbidities. To assess the relative strength of risk factors for predicting the occurrence of delirium, we performed a random-forest survival analysis.
Results: 347 patients with positive COVID-19 PCR test and median age 68.2 [IQR 55.5, 80.5] years were included. Of those, 79 patients (22.8%) developed delirium, 81 (23.3%) were transferred to ICU, 58 (16.7%) died. 163 (73.8%) patients were discharged home, 13 (5.9%) to another hospital, 32 (14.5%) to nursing homes, 13 (5.9%) to rehabilitation with an overall median admission-to-discharge time of 53 [IQR 14, 195] days. The strongest predictors for the occurrence of delirium were blood urea nitrogen (minimal depth value (MD): 3.33), age (MD: 3.75), disease severity (as captured by WHO grading; MD: 3.93), leukocyte count (MD: 4.22), the presence of a neurodegenerative history (MD: 4.43), ferritin (MD: 4.46) and creatinine (MD: 4.59) levels.
Conclusion: The risk of delirium in COVID-19 can be stratified based on COVID-19 disease severity and-similar to delirium associated with other respiratory infections-the factors advanced age, neurodegenerative disease history, and presence of elevated infection and renal-retention parameters. Screening for these risk factors may facilitate early identification of patients at high-risk for COVID-19-associated delirium.
. 2022 Dec 22;17(12):e0278214.
doi: 10.1371/journal.pone.0278214. eCollection 2022.
Delirium in hospitalized COVID-19 patients: Predictors and implications for patient outcome
Vera Wilke[SUP] 1 2 [/SUP], Mihaly Sulyok[SUP] 3 [/SUP], Maria-Ioanna Stefanou[SUP] 4 [/SUP], Vivien Richter[SUP] 5 [/SUP], Benjamin Bender[SUP] 5 [/SUP], Ulrike Ernemann[SUP] 5 [/SUP], Ulf Ziemann[SUP] 1 2 [/SUP], Nisar Malek[SUP] 6 [/SUP], Katharina Kienzle[SUP] 7 [/SUP], Constantin Klein[SUP] 6 [/SUP], Stefanie Bunk[SUP] 6 [/SUP], Siri Goepel[SUP] 6 7 [/SUP], Annerose Mengel[SUP] 1 2 [/SUP]
Affiliations
- PMID: 36548347
- DOI: 10.1371/journal.pone.0278214
Abstract
Introduction: Delirium is recognized as a severe complication of coronavirus-disease-2019 (COVID-19). COVID-19-associated delirium has been linked to worse patient outcomes and is considered to be of multifactorial origin. Here we sought to evaluate the incidence and risk factors of delirium in hospitalized COVID-19 patients, along with its impact on clinical outcome.
Methods: Consecutive adult COVID-19 patients admitted to a tertiary academic referral hospital between March 1st and December 31st, 2020 were included. Potential risk factors for delirium were evaluated, including: age, gender, disease severity (as per the highest WHO grading reached during admission), laboratory parameters for infection and renal function (as per their most extreme values), and presence of comorbidities. To assess the relative strength of risk factors for predicting the occurrence of delirium, we performed a random-forest survival analysis.
Results: 347 patients with positive COVID-19 PCR test and median age 68.2 [IQR 55.5, 80.5] years were included. Of those, 79 patients (22.8%) developed delirium, 81 (23.3%) were transferred to ICU, 58 (16.7%) died. 163 (73.8%) patients were discharged home, 13 (5.9%) to another hospital, 32 (14.5%) to nursing homes, 13 (5.9%) to rehabilitation with an overall median admission-to-discharge time of 53 [IQR 14, 195] days. The strongest predictors for the occurrence of delirium were blood urea nitrogen (minimal depth value (MD): 3.33), age (MD: 3.75), disease severity (as captured by WHO grading; MD: 3.93), leukocyte count (MD: 4.22), the presence of a neurodegenerative history (MD: 4.43), ferritin (MD: 4.46) and creatinine (MD: 4.59) levels.
Conclusion: The risk of delirium in COVID-19 can be stratified based on COVID-19 disease severity and-similar to delirium associated with other respiratory infections-the factors advanced age, neurodegenerative disease history, and presence of elevated infection and renal-retention parameters. Screening for these risk factors may facilitate early identification of patients at high-risk for COVID-19-associated delirium.